Breast Cancer Clinical Trial
Official title:
A Multicenter Open-label Non-comparative 2-Stage Phase 1a/1b Study to Assess the Safety and Pharmacokinetics of BCD-115 (JSC BIOCAD, Russia) in Combination With Endocrine Therapy in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer
Verified date | March 2018 |
Source | Biocad |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A Multicenter Open-label Non-comparative 2-Stage Phase 1a/1b Study to Assess the Safety and Pharmacokinetics of Oral BCD-115 (JSC BIOCAD, Russia) in Combination with Endocrine Therapy in Women with ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer
Status | Completed |
Enrollment | 6 |
Est. completion date | March 2018 |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Written informed consent and ability to follow the Protocol procedures; 2. Age =18 years; 3. Female gender; 4. Postmenopausal status (Prior bilateral surgical oophorectomy; or medically confirmed post-menopausal status defined as spontaneous cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause); 5. Histologically proven diagnosis of adenocarcinoma of the breast with evidence of metastatic disease; 6. Progression of advanced breast cancer on first line endocrine therapy for advanced breast cancer. 7. ER positive tumor = 10%; 8. HER2 negative breast cancer by FISH or IHC; 9. Eastern Cooperative Oncology Group (ECOG) performance status 0 -2 10. Measurable disease according to RECIST 1.1 (only bone disease is not allowed) 11. Resolution of all acute toxic effects of prior therapy (including endocrine therapy) or surgical procedures to CTCAE grade =1 12. Adequate organ function; 13. Life expectancy - 12 weeks or more from the moment of randomization Exclusion Criteria: 1. HER2-positive tumour ; 2. Patients with unstable brain metastases, advanced, symptomatic, visceral spread disease, that are at risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions pleural, pericardial, peritoneal, pulmonary lymphangitis, and over 50% liver involvement). 3. Important cardiovascular events in the past 6 months to randomization; 4. GI diseases which may affect the absorption of the study drug; 5. Inadequate hematopoietic function: neutrophils =1500/mm3, platelets =100 000/mm3,or hemoglobin =90 g/L; 6. Inadequate renal function: creatinine level = 1.5 × upper limit of normal (ULN); 7. Inadequate liver function: bilirubin level = 1.5 × ULN, AST and ALT levels = 2.5 × ULN (5 × ULN for patients with liver metastases), alkaline phosphatase level = 5 × ULN; 8. Concurrent antitumor treatment 21 days before randomization (surgery, radiation therapy; chemotherapy, except endocrine therapy); 9. Any other concomitant cancer including contralateral breast cancer revealed within 5 years prior to screening, except curatively treated intraductal carcinoma in situ, curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma; 10. Conditions limiting patient's adherence to protocol requirements (dementia, neurologic or psychiatric disorders, drug addiction, alcoholism and others); 11. Concomitant participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial; 12. Acute or active chronic infections; 13. HCV, HBV, HIV or syphilis infections; 14. Obstacles to p.o. administration of study drug. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | N.N. Blokhin Russian Cancer Research Center | Sankt Petersburg |
Lead Sponsor | Collaborator |
---|---|
Biocad |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the plasma concentration versus time curve (AUC0-t) | To determine AUC0-t after single doses of BCD-115 p.o. administration with dose escalation; | 90 days | |
Primary | Peak Plasma Concentration (Cmax) | To determine observed maximum concentration in plasma or serums after single doses of BCD-115 p.o. administration with dose | 90 days | |
Primary | The incidence and severity of AEs | The incidence and severity of AEs (%) related with the therapy based on results of review by 3 experts (%) | 90 days | |
Primary | The incidence of grade 3-4 AEs | The incidence of grade 3-4 AEs (%) related with the therapy based on results of review by 3 experts | 90 days | |
Secondary | Treatment discontinuation due to adverse events | Treatment discontinuation due to adverse events (%) | 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |